$317 Million is the total value of Endurant Capital Management LP's 54 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | New | REGENERON PHARMACEUTICALS | $10,284,000 | – | 27,390 | +100.0% | 3.24% | – |
| SIBN | New | SI BONE INC | $10,114,000 | – | 470,429 | +100.0% | 3.19% | – |
| IQV | New | IQVIA HLDGS INC | $7,692,000 | – | 49,781 | +100.0% | 2.42% | – |
| HRC | New | HILL ROM HLDGS INC | $7,475,000 | – | 65,843 | +100.0% | 2.36% | – |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $6,102,000 | – | 89,614 | +100.0% | 1.92% | – |
| EVH | New | EVOLENT HEALTH INCcl a | $5,406,000 | – | 597,303 | +100.0% | 1.70% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $5,139,000 | – | 39,822 | +100.0% | 1.62% | – |
| MDRX | New | ALLSCRIPTS HEALTHCARE SOLUTN | $4,397,000 | – | 447,986 | +100.0% | 1.38% | – |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $3,624,000 | – | 66,157 | +100.0% | 1.14% | – |
| XRAY | New | DENTSPLY SIRONA INC | $3,210,000 | – | 56,725 | +100.0% | 1.01% | – |
| BAX | New | BAXTER INTL INC | $2,856,000 | – | 34,151 | +100.0% | 0.90% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $2,475,000 | – | 214,823 | +100.0% | 0.78% | – |
| SILK | New | SILK ROAD MEDICAL INC | $2,072,000 | – | 51,303 | +100.0% | 0.65% | – |
| AHCO | New | ADAPTHEALTH CORP | $1,843,000 | – | 167,858 | +100.0% | 0.58% | – |
| MCK | New | MCKESSON CORP | $1,438,000 | – | 10,396 | +100.0% | 0.45% | – |
| MGNX | New | MACROGENICS INC | $1,337,000 | – | 122,900 | +100.0% | 0.42% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $1,273,000 | – | 21,361 | +100.0% | 0.40% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $1,153,000 | – | 11,151 | +100.0% | 0.36% | – |
| DVA | New | DAVITA INC | $901,000 | – | 12,002 | +100.0% | 0.28% | – |
| STRO | New | SUTRO BIOPHARMA INC | $359,000 | – | 32,666 | +100.0% | 0.11% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $303,000 | – | 13,768 | +100.0% | 0.10% | – |
| PTI | New | PROTEOSTASIS THERAPEUTICS INcall | $108,000 | – | 47,400 | +100.0% | 0.03% | – |
| ACRS | New | ACLARIS THERAPEUTICS INCcall | $94,000 | – | 376,200 | +100.0% | 0.03% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $61,000 | – | 25,788 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.